IRVINE, Calif.–(BUSINESS WIRE)–Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to present at the J.P. Morgan Healthcare conference at 5:15 p.m. Pacific Time on Monday, January 8, 2024.
Interested parties may access a live webcast and replay of the presentation by visiting the Axonics investor relations website.
About Axonics
Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times list of the fastest growing companies in the Americas after being ranked No. 1 in 2022.
Axonics® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. For more information, visit www.axonics.com.
Contacts
Neil Bhalodkar
949-336-5293
IR@axonics.com
Huawei wearable devices Surpassed 200 Million Cumulative Shipments SHENZHEN, China, June 14, 2025 /PRNewswire/ -- According to…
ALPHARETTA, Ga., June 13, 2025 /PRNewswire/ -- Decisely learned of a data security incident that may…
NEW YORK--(BUSINESS WIRE)--#digitalhealth--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians…
Veteran Leader Brings Deep Industry Expertise to Advance Berwyn's Healthcare Strategy INDEPENDENCE, Ohio, June 13,…
BOLOGNA, Italy, June 13, 2025 /PRNewswire/ -- Datalogic, a global leader in the automatic data capture…
PORTLAND, Ore., June 13, 2025 /PRNewswire/ -- Skypoint, a leading provider of HITRUST r2-certified AI platform…